REGENXBIO

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell REGENXBIO and other ETFs, options, and stocks.

About RGNX

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. 

CEO
Kenneth T. Mills
CEOKenneth T. Mills
Employees
372
Employees372
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
2008
Founded2008
Employees
372
Employees372

RGNX Key Statistics

Market cap
977.14M
Market cap977.14M
Price-Earnings ratio
14.40
Price-Earnings ratio14.40
Dividend yield
Dividend yield
Average volume
265.14K
Average volume265.14K
High today
$22.99
High today$22.99
Low today
$22.09
Low today$22.09
Open price
$22.51
Open price$22.51
Volume
199.72K
Volume199.72K
52 Week high
$36.35
52 Week high$36.35
52 Week low
$18.69
52 Week low$18.69

Analyst ratings

67%

of 9 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

RGNX Earnings

-$1.75
$1.06
$3.86
$6.67
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Estimated
per share
Estimated per share
Actual
Expected Mar 1, Pre-Market
ActualExpected Mar 1, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.